| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nephrology | 46 | 2021 | 153 | 10.670 |
Why?
|
| Kidney Diseases | 64 | 2020 | 505 | 8.120 |
Why?
|
| Renal Dialysis | 53 | 2020 | 891 | 4.040 |
Why?
|
| Kidney Failure, Chronic | 48 | 2020 | 915 | 3.180 |
Why?
|
| History, 19th Century | 35 | 2023 | 120 | 2.880 |
Why?
|
| History, 20th Century | 37 | 2023 | 396 | 2.780 |
Why?
|
| Kidney | 68 | 2024 | 1421 | 2.360 |
Why?
|
| Nephritis, Interstitial | 6 | 2023 | 40 | 2.140 |
Why?
|
| History, 18th Century | 26 | 2020 | 71 | 2.100 |
Why?
|
| History, 17th Century | 25 | 2020 | 35 | 1.960 |
Why?
|
| Terminology as Topic | 6 | 2020 | 234 | 1.720 |
Why?
|
| Uremia | 13 | 2018 | 36 | 1.700 |
Why?
|
| Practice Guidelines as Topic | 22 | 2010 | 1340 | 1.700 |
Why?
|
| History, Ancient | 23 | 2019 | 56 | 1.690 |
Why?
|
| History, 16th Century | 22 | 2019 | 27 | 1.600 |
Why?
|
| Acute Kidney Injury | 25 | 2015 | 704 | 1.490 |
Why?
|
| History, Medieval | 17 | 2015 | 28 | 1.290 |
Why?
|
| Phosphorus | 3 | 2024 | 61 | 1.190 |
Why?
|
| Humans | 213 | 2024 | 134156 | 1.080 |
Why?
|
| Albuminuria | 8 | 2017 | 115 | 1.030 |
Why?
|
| Medicine, Arabic | 3 | 2015 | 3 | 0.980 |
Why?
|
| Kidney Glomerulus | 17 | 2019 | 84 | 0.930 |
Why?
|
| Kidneys, Artificial | 4 | 2009 | 5 | 0.910 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2019 | 807 | 0.880 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2024 | 16 | 0.880 |
Why?
|
| Transplants | 1 | 2024 | 37 | 0.850 |
Why?
|
| Acid-Base Imbalance | 2 | 2022 | 27 | 0.790 |
Why?
|
| Alkalosis | 1 | 2022 | 24 | 0.790 |
Why?
|
| Physiology | 3 | 2016 | 13 | 0.790 |
Why?
|
| Health Policy | 2 | 2020 | 233 | 0.780 |
Why?
|
| Proteinuria | 10 | 2011 | 114 | 0.770 |
Why?
|
| Acidosis | 3 | 2022 | 104 | 0.750 |
Why?
|
| Pyelonephritis | 7 | 2019 | 29 | 0.720 |
Why?
|
| Glomerular Filtration Rate | 38 | 2014 | 549 | 0.690 |
Why?
|
| Phytotherapy | 2 | 2015 | 51 | 0.690 |
Why?
|
| Famous Persons | 3 | 2013 | 17 | 0.690 |
Why?
|
| Hepatorenal Syndrome | 1 | 2021 | 32 | 0.680 |
Why?
|
| Nephritis | 4 | 2020 | 24 | 0.680 |
Why?
|
| History, 21st Century | 6 | 2020 | 277 | 0.670 |
Why?
|
| Chronic Disease | 19 | 2011 | 1250 | 0.660 |
Why?
|
| Renal Circulation | 3 | 2015 | 46 | 0.660 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 297 | 0.660 |
Why?
|
| Uromodulin | 1 | 2019 | 13 | 0.620 |
Why?
|
| Lupus Nephritis | 1 | 2019 | 43 | 0.610 |
Why?
|
| Diuretics | 12 | 2015 | 169 | 0.600 |
Why?
|
| History, 15th Century | 8 | 2013 | 14 | 0.590 |
Why?
|
| Forecasting | 4 | 2019 | 377 | 0.590 |
Why?
|
| Global Health | 5 | 2007 | 622 | 0.580 |
Why?
|
| Quality Assurance, Health Care | 5 | 2004 | 221 | 0.550 |
Why?
|
| Foundations | 8 | 2003 | 22 | 0.530 |
Why?
|
| Urea | 12 | 2018 | 238 | 0.510 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2014 | 1218 | 0.500 |
Why?
|
| Medical Illustration | 3 | 2012 | 18 | 0.490 |
Why?
|
| Kidney Tubules | 22 | 2011 | 78 | 0.490 |
Why?
|
| Evidence-Based Medicine | 10 | 2011 | 682 | 0.490 |
Why?
|
| Diabetes Insipidus | 5 | 2011 | 17 | 0.490 |
Why?
|
| Peritoneal Dialysis | 6 | 2007 | 132 | 0.480 |
Why?
|
| Urinalysis | 4 | 2012 | 66 | 0.480 |
Why?
|
| Diabetic Nephropathies | 6 | 2006 | 114 | 0.480 |
Why?
|
| Anemia | 6 | 2008 | 349 | 0.470 |
Why?
|
| Anatomy | 5 | 2012 | 11 | 0.460 |
Why?
|
| Disease Progression | 9 | 2019 | 2266 | 0.440 |
Why?
|
| Water-Electrolyte Balance | 12 | 2010 | 83 | 0.430 |
Why?
|
| Membranes, Artificial | 3 | 2003 | 30 | 0.430 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 680 | 0.430 |
Why?
|
| Renal Replacement Therapy | 5 | 2013 | 157 | 0.420 |
Why?
|
| Plant Extracts | 1 | 2015 | 138 | 0.420 |
Why?
|
| Obesity | 4 | 2011 | 2446 | 0.420 |
Why?
|
| Manuscripts, Medical as Topic | 6 | 2009 | 8 | 0.420 |
Why?
|
| Music | 1 | 2013 | 17 | 0.420 |
Why?
|
| Anemia, Sickle Cell | 2 | 2017 | 346 | 0.410 |
Why?
|
| Physicians, Women | 1 | 2013 | 52 | 0.400 |
Why?
|
| Cardiovascular Diseases | 10 | 2011 | 2090 | 0.400 |
Why?
|
| Carnitine | 2 | 2003 | 78 | 0.400 |
Why?
|
| Reference Books, Medical | 1 | 2012 | 4 | 0.390 |
Why?
|
| Pulse | 1 | 2012 | 29 | 0.390 |
Why?
|
| Medicine, Traditional | 2 | 2009 | 7 | 0.390 |
Why?
|
| Textbooks as Topic | 2 | 2012 | 8 | 0.380 |
Why?
|
| Liver Transplantation | 1 | 2021 | 1128 | 0.370 |
Why?
|
| Dictionaries as Topic | 1 | 2011 | 3 | 0.360 |
Why?
|
| Encyclopedias as Topic | 1 | 2011 | 7 | 0.360 |
Why?
|
| Hemodialysis Solutions | 2 | 2002 | 6 | 0.360 |
Why?
|
| Hyperphosphatemia | 3 | 2011 | 19 | 0.350 |
Why?
|
| France | 4 | 2018 | 89 | 0.340 |
Why?
|
| Obstetrics | 1 | 2013 | 240 | 0.340 |
Why?
|
| Guidelines as Topic | 2 | 2009 | 203 | 0.340 |
Why?
|
| Glomerulonephritis | 14 | 2011 | 77 | 0.340 |
Why?
|
| International Cooperation | 3 | 2011 | 169 | 0.330 |
Why?
|
| Creatinine | 16 | 2007 | 429 | 0.330 |
Why?
|
| Diabetes Mellitus | 4 | 2011 | 937 | 0.330 |
Why?
|
| Ureteral Obstruction | 2 | 2011 | 109 | 0.330 |
Why?
|
| Risk Factors | 16 | 2024 | 11182 | 0.320 |
Why?
|
| Juxtaglomerular Apparatus | 1 | 2009 | 7 | 0.320 |
Why?
|
| beta 2-Microglobulin | 2 | 2007 | 34 | 0.320 |
Why?
|
| Kidney Function Tests | 12 | 2021 | 137 | 0.320 |
Why?
|
| Phosphates | 16 | 2008 | 121 | 0.310 |
Why?
|
| Persia | 4 | 2015 | 4 | 0.310 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2008 | 9 | 0.300 |
Why?
|
| Chitosan | 1 | 2009 | 32 | 0.300 |
Why?
|
| Saliva | 2 | 2009 | 133 | 0.300 |
Why?
|
| Kidney Diseases, Cystic | 2 | 2008 | 41 | 0.290 |
Why?
|
| Medicine in the Arts | 3 | 2012 | 8 | 0.290 |
Why?
|
| Disasters | 3 | 2003 | 106 | 0.290 |
Why?
|
| Biopsy | 8 | 2019 | 1304 | 0.290 |
Why?
|
| United States | 23 | 2020 | 11763 | 0.290 |
Why?
|
| Military Medicine | 1 | 2008 | 51 | 0.290 |
Why?
|
| Internationality | 1 | 2008 | 138 | 0.280 |
Why?
|
| Biomarkers | 7 | 2019 | 3434 | 0.270 |
Why?
|
| Acid-Base Equilibrium | 4 | 2022 | 61 | 0.260 |
Why?
|
| Religion and Medicine | 3 | 2009 | 25 | 0.260 |
Why?
|
| Prevalence | 8 | 2014 | 2684 | 0.250 |
Why?
|
| Diabetes Complications | 1 | 2007 | 206 | 0.250 |
Why?
|
| Bible | 1 | 2005 | 1 | 0.250 |
Why?
|
| Ceremonial Behavior | 1 | 2005 | 5 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 1356 | 0.250 |
Why?
|
| Severity of Illness Index | 4 | 2011 | 3114 | 0.250 |
Why?
|
| Therapeutics | 1 | 2005 | 8 | 0.230 |
Why?
|
| Body Mass Index | 3 | 2010 | 1719 | 0.230 |
Why?
|
| Genetics, Medical | 1 | 2006 | 123 | 0.230 |
Why?
|
| Complementary Therapies | 1 | 2005 | 42 | 0.230 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 1996 | 316 | 0.230 |
Why?
|
| Electrolytes | 5 | 2022 | 55 | 0.230 |
Why?
|
| Hypertension, Renal | 2 | 2004 | 41 | 0.230 |
Why?
|
| Analgesics | 3 | 1996 | 133 | 0.220 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 394 | 0.220 |
Why?
|
| Knowledge | 1 | 2024 | 51 | 0.220 |
Why?
|
| Male | 85 | 2017 | 66127 | 0.220 |
Why?
|
| Language | 2 | 2021 | 222 | 0.220 |
Why?
|
| Sodium | 32 | 2002 | 309 | 0.220 |
Why?
|
| Internet | 1 | 2007 | 403 | 0.220 |
Why?
|
| Endocrinology | 2 | 2004 | 135 | 0.220 |
Why?
|
| Homeostasis | 3 | 2024 | 751 | 0.210 |
Why?
|
| England | 3 | 2016 | 72 | 0.210 |
Why?
|
| Transplantation, Homologous | 5 | 2024 | 690 | 0.210 |
Why?
|
| Quality of Health Care | 2 | 2008 | 420 | 0.210 |
Why?
|
| Transplantation, Heterologous | 1 | 2024 | 276 | 0.210 |
Why?
|
| Hydrogen-Ion Concentration | 6 | 2022 | 470 | 0.210 |
Why?
|
| Minerals | 3 | 2008 | 59 | 0.200 |
Why?
|
| Disaster Planning | 2 | 2003 | 64 | 0.200 |
Why?
|
| Relief Work | 1 | 2003 | 31 | 0.200 |
Why?
|
| Nephrotic Syndrome | 8 | 2005 | 52 | 0.200 |
Why?
|
| Alkalies | 1 | 2022 | 25 | 0.200 |
Why?
|
| Middle Aged | 45 | 2013 | 29399 | 0.200 |
Why?
|
| Dialysis | 1 | 2002 | 21 | 0.190 |
Why?
|
| Urine | 8 | 2007 | 92 | 0.190 |
Why?
|
| Prognosis | 5 | 2019 | 5086 | 0.190 |
Why?
|
| Female | 74 | 2017 | 71928 | 0.190 |
Why?
|
| Interinstitutional Relations | 1 | 2001 | 21 | 0.180 |
Why?
|
| Animals | 56 | 2024 | 36557 | 0.180 |
Why?
|
| Early Diagnosis | 2 | 2014 | 200 | 0.180 |
Why?
|
| Total Quality Management | 1 | 2001 | 27 | 0.170 |
Why?
|
| Treatment Outcome | 12 | 2014 | 13074 | 0.170 |
Why?
|
| Metabolic Syndrome | 1 | 2024 | 365 | 0.170 |
Why?
|
| Paintings | 1 | 2000 | 3 | 0.170 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 146 | 0.160 |
Why?
|
| Hypertension | 8 | 2011 | 1398 | 0.160 |
Why?
|
| Edema | 3 | 1997 | 140 | 0.160 |
Why?
|
| Adult | 45 | 2013 | 31945 | 0.160 |
Why?
|
| Hemoglobins | 4 | 2008 | 322 | 0.160 |
Why?
|
| Neoplasms | 2 | 2013 | 3038 | 0.160 |
Why?
|
| Armenia | 3 | 2009 | 4 | 0.160 |
Why?
|
| Mummies | 1 | 1999 | 1 | 0.150 |
Why?
|
| Kidney Tubules, Proximal | 9 | 1985 | 112 | 0.150 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2011 | 267 | 0.150 |
Why?
|
| Belgium | 2 | 2009 | 44 | 0.150 |
Why?
|
| Kidney Concentrating Ability | 13 | 1983 | 16 | 0.150 |
Why?
|
| Parathyroid Glands | 5 | 1995 | 29 | 0.150 |
Why?
|
| Cardiology | 1 | 2004 | 521 | 0.150 |
Why?
|
| Calcium | 18 | 2008 | 1148 | 0.150 |
Why?
|
| Polyuria | 2 | 2010 | 11 | 0.150 |
Why?
|
| Rats | 20 | 2011 | 3890 | 0.150 |
Why?
|
| Bacteriuria | 1 | 2019 | 83 | 0.140 |
Why?
|
| Education, Medical | 2 | 2012 | 302 | 0.140 |
Why?
|
| Europe | 3 | 2011 | 382 | 0.140 |
Why?
|
| Mercury | 5 | 1997 | 30 | 0.140 |
Why?
|
| Neurology | 2 | 2011 | 120 | 0.140 |
Why?
|
| Predictive Value of Tests | 4 | 2014 | 2301 | 0.140 |
Why?
|
| Time Factors | 19 | 2011 | 6610 | 0.140 |
Why?
|
| Research Design | 2 | 2004 | 748 | 0.130 |
Why?
|
| Dialysis Solutions | 1 | 1997 | 12 | 0.130 |
Why?
|
| Anatomy, Artistic | 1 | 1997 | 8 | 0.130 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 2 | 2007 | 13 | 0.130 |
Why?
|
| Blood Coagulation Disorders | 1 | 1998 | 110 | 0.130 |
Why?
|
| Proportional Hazards Models | 7 | 2011 | 1488 | 0.130 |
Why?
|
| Vasopressins | 7 | 2010 | 45 | 0.130 |
Why?
|
| Diabetic Ketoacidosis | 5 | 1989 | 169 | 0.130 |
Why?
|
| Aged | 20 | 2013 | 21775 | 0.130 |
Why?
|
| Acute Disease | 2 | 2019 | 1192 | 0.130 |
Why?
|
| Periodicals as Topic | 2 | 2011 | 201 | 0.130 |
Why?
|
| Blood Urea Nitrogen | 13 | 2002 | 77 | 0.130 |
Why?
|
| Polyradiculoneuropathy | 1 | 1996 | 6 | 0.130 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 1996 | 14 | 0.120 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2003 | 140 | 0.120 |
Why?
|
| Mesopotamia | 1 | 2015 | 1 | 0.120 |
Why?
|
| Demyelinating Diseases | 1 | 1996 | 71 | 0.120 |
Why?
|
| Greece | 1 | 2015 | 11 | 0.120 |
Why?
|
| Egypt | 1 | 2015 | 30 | 0.120 |
Why?
|
| Italy | 4 | 2000 | 130 | 0.120 |
Why?
|
| Chemistry, Physical | 2 | 2014 | 31 | 0.120 |
Why?
|
| Follow-Up Studies | 6 | 2011 | 5477 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 4 | 2011 | 294 | 0.110 |
Why?
|
| Science | 1 | 2015 | 37 | 0.110 |
Why?
|
| Cell Biology | 1 | 2014 | 4 | 0.110 |
Why?
|
| Reference Values | 2 | 2007 | 741 | 0.110 |
Why?
|
| Antigen-Antibody Complex | 7 | 1979 | 67 | 0.110 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2007 | 59 | 0.110 |
Why?
|
| Potassium | 23 | 1986 | 290 | 0.110 |
Why?
|
| Liver Cirrhosis | 2 | 2021 | 947 | 0.110 |
Why?
|
| Herbal Medicine | 1 | 2013 | 5 | 0.110 |
Why?
|
| Malacoplakia | 1 | 1993 | 3 | 0.110 |
Why?
|
| Remission Induction | 1 | 2014 | 310 | 0.110 |
Why?
|
| Multiple Myeloma | 3 | 2012 | 202 | 0.110 |
Why?
|
| Patient Advocacy | 1 | 2013 | 63 | 0.100 |
Why?
|
| Steroids | 1 | 2014 | 213 | 0.100 |
Why?
|
| Renal Insufficiency | 2 | 1994 | 255 | 0.100 |
Why?
|
| Clonidine | 2 | 1983 | 37 | 0.100 |
Why?
|
| Kidney Transplantation | 7 | 2007 | 691 | 0.100 |
Why?
|
| Lymphocytosis | 1 | 2012 | 14 | 0.100 |
Why?
|
| Aging | 2 | 1996 | 1306 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2011 | 252 | 0.100 |
Why?
|
| Alchemy | 1 | 2012 | 3 | 0.100 |
Why?
|
| Incunabula as Topic | 1 | 2012 | 1 | 0.100 |
Why?
|
| Societies, Medical | 2 | 2011 | 778 | 0.100 |
Why?
|
| Information Dissemination | 1 | 2014 | 199 | 0.100 |
Why?
|
| Glucose | 6 | 2005 | 927 | 0.100 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2012 | 77 | 0.100 |
Why?
|
| Chemistry | 1 | 2012 | 61 | 0.100 |
Why?
|
| Quackery | 1 | 2011 | 2 | 0.090 |
Why?
|
| Autopsy | 2 | 2012 | 120 | 0.090 |
Why?
|
| Malnutrition | 2 | 2006 | 221 | 0.090 |
Why?
|
| World War II | 1 | 2011 | 6 | 0.090 |
Why?
|
| Numismatics | 1 | 2011 | 3 | 0.090 |
Why?
|
| Germany | 1 | 2011 | 60 | 0.090 |
Why?
|
| Turkey | 1 | 2011 | 67 | 0.090 |
Why?
|
| Hemodialysis, Home | 1 | 2011 | 12 | 0.090 |
Why?
|
| Endocarditis, Bacterial | 6 | 1985 | 138 | 0.090 |
Why?
|
| Survival Analysis | 5 | 2011 | 1599 | 0.090 |
Why?
|
| Uric Acid | 8 | 1976 | 110 | 0.090 |
Why?
|
| Models, Biological | 2 | 2007 | 1539 | 0.090 |
Why?
|
| Equipment Design | 2 | 2011 | 608 | 0.090 |
Why?
|
| Magnesium | 8 | 1984 | 127 | 0.080 |
Why?
|
| Pituitary Gland | 1 | 2010 | 89 | 0.080 |
Why?
|
| Bicarbonates | 9 | 2002 | 100 | 0.080 |
Why?
|
| Prospective Studies | 6 | 2011 | 6601 | 0.080 |
Why?
|
| Atrophy | 1 | 2011 | 254 | 0.080 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2011 | 161 | 0.080 |
Why?
|
| Hemodynamics | 2 | 2007 | 873 | 0.080 |
Why?
|
| Materia Medica | 1 | 2009 | 2 | 0.080 |
Why?
|
| Internal Medicine | 1 | 2011 | 159 | 0.080 |
Why?
|
| Christianity | 1 | 2009 | 14 | 0.080 |
Why?
|
| Substance-Related Disorders | 5 | 1985 | 492 | 0.080 |
Why?
|
| Antihypertensive Agents | 3 | 1991 | 410 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 2011 | 248 | 0.080 |
Why?
|
| Classification | 1 | 2009 | 19 | 0.080 |
Why?
|
| Muscles | 1 | 2010 | 279 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2015 | 556 | 0.080 |
Why?
|
| Chewing Gum | 1 | 2009 | 10 | 0.080 |
Why?
|
| Diagnosis | 1 | 2009 | 30 | 0.080 |
Why?
|
| Hypothalamus | 1 | 2010 | 223 | 0.080 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 1979 | 0.080 |
Why?
|
| Heart Diseases | 2 | 2007 | 526 | 0.080 |
Why?
|
| Crush Syndrome | 2 | 2003 | 4 | 0.080 |
Why?
|
| Immunoglobulin G | 8 | 1977 | 825 | 0.080 |
Why?
|
| Health Education | 1 | 2010 | 230 | 0.070 |
Why?
|
| Hyperlipidemias | 2 | 2002 | 198 | 0.070 |
Why?
|
| Polycystic Kidney Diseases | 3 | 1977 | 33 | 0.070 |
Why?
|
| Dogs | 27 | 1984 | 798 | 0.070 |
Why?
|
| Adiposity | 1 | 2010 | 207 | 0.070 |
Why?
|
| Philately | 1 | 2007 | 1 | 0.070 |
Why?
|
| Dehydration | 4 | 2005 | 42 | 0.070 |
Why?
|
| Cranial Nerves | 1 | 2007 | 20 | 0.070 |
Why?
|
| Canada | 1 | 2008 | 346 | 0.070 |
Why?
|
| Public Health | 2 | 2007 | 287 | 0.070 |
Why?
|
| Risk Assessment | 4 | 2011 | 3743 | 0.070 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 2 | 1998 | 21 | 0.070 |
Why?
|
| Safety Management | 1 | 2008 | 121 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 7217 | 0.070 |
Why?
|
| Sodium Chloride | 10 | 1976 | 99 | 0.070 |
Why?
|
| Weight Loss | 1 | 2011 | 516 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2005 | 827 | 0.070 |
Why?
|
| Policy Making | 1 | 2007 | 62 | 0.070 |
Why?
|
| Hepatitis C | 1 | 2011 | 389 | 0.070 |
Why?
|
| Beauty | 1 | 2006 | 4 | 0.070 |
Why?
|
| Bucladesine | 3 | 1975 | 21 | 0.070 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 139 | 0.070 |
Why?
|
| Angiotensin II | 2 | 1987 | 173 | 0.060 |
Why?
|
| Parathyroid Hormone | 6 | 2008 | 79 | 0.060 |
Why?
|
| Physicians | 1 | 2013 | 639 | 0.060 |
Why?
|
| Algorithms | 2 | 2004 | 1736 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2010 | 448 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2007 | 148 | 0.060 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 1977 | 43 | 0.060 |
Why?
|
| Culture | 1 | 2006 | 73 | 0.060 |
Why?
|
| Dietary Proteins | 4 | 2002 | 252 | 0.060 |
Why?
|
| Survival Rate | 2 | 2008 | 2218 | 0.060 |
Why?
|
| Translations | 1 | 2005 | 18 | 0.060 |
Why?
|
| Catheters, Indwelling | 1 | 2007 | 159 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2011 | 700 | 0.060 |
Why?
|
| Food | 1 | 2006 | 140 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2011 | 3754 | 0.060 |
Why?
|
| Renal Artery | 3 | 1985 | 70 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2011 | 824 | 0.060 |
Why?
|
| Iron | 1 | 2008 | 305 | 0.060 |
Why?
|
| Calcinosis | 1 | 2007 | 193 | 0.060 |
Why?
|
| Renal Veins | 1 | 1985 | 34 | 0.060 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 1986 | 57 | 0.060 |
Why?
|
| Pancreatic Diseases | 1 | 2005 | 40 | 0.060 |
Why?
|
| Organotherapy | 1 | 2004 | 2 | 0.060 |
Why?
|
| Endocrine Glands | 1 | 2004 | 11 | 0.060 |
Why?
|
| Gonads | 1 | 2004 | 35 | 0.060 |
Why?
|
| Vasculitis | 1 | 1985 | 51 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2007 | 471 | 0.060 |
Why?
|
| Diet, Sodium-Restricted | 3 | 1999 | 18 | 0.060 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2004 | 72 | 0.060 |
Why?
|
| Hypertension, Renovascular | 1 | 2004 | 29 | 0.060 |
Why?
|
| Body Constitution | 1 | 2004 | 42 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2008 | 574 | 0.050 |
Why?
|
| Family Practice | 1 | 2004 | 92 | 0.050 |
Why?
|
| Immune Complex Diseases | 3 | 1979 | 5 | 0.050 |
Why?
|
| Osmolar Concentration | 12 | 1986 | 179 | 0.050 |
Why?
|
| Microscopy, Electron | 8 | 1990 | 367 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2003 | 145 | 0.050 |
Why?
|
| Apoptosis | 1 | 2011 | 1946 | 0.050 |
Why?
|
| New York City | 1 | 2003 | 64 | 0.050 |
Why?
|
| Adenosine Diphosphate | 2 | 1981 | 55 | 0.050 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2003 | 3 | 0.050 |
Why?
|
| Scleroderma, Systemic | 1 | 1985 | 130 | 0.050 |
Why?
|
| Diuresis | 18 | 1976 | 58 | 0.050 |
Why?
|
| Blood Platelets | 2 | 1981 | 342 | 0.050 |
Why?
|
| Diarrhea | 1 | 2005 | 343 | 0.050 |
Why?
|
| Adenosine Triphosphatases | 3 | 1981 | 217 | 0.050 |
Why?
|
| Body Composition | 1 | 2005 | 562 | 0.050 |
Why?
|
| Roman World | 1 | 2002 | 2 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2004 | 157 | 0.050 |
Why?
|
| Organomercury Compounds | 4 | 1997 | 8 | 0.050 |
Why?
|
| Epidemiologic Methods | 1 | 2002 | 111 | 0.050 |
Why?
|
| Indomethacin | 2 | 1980 | 86 | 0.050 |
Why?
|
| Kidney Papillary Necrosis | 1 | 1982 | 1 | 0.050 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2003 | 152 | 0.050 |
Why?
|
| Information Systems | 1 | 2002 | 34 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2004 | 338 | 0.050 |
Why?
|
| Complement C1 | 2 | 1979 | 4 | 0.050 |
Why?
|
| Fatigue | 1 | 2003 | 201 | 0.050 |
Why?
|
| Health Planning | 1 | 2001 | 16 | 0.050 |
Why?
|
| Hypotension | 2 | 2003 | 190 | 0.050 |
Why?
|
| Physicians, Family | 1 | 2001 | 38 | 0.050 |
Why?
|
| Cause of Death | 3 | 2011 | 507 | 0.050 |
Why?
|
| Risk | 4 | 2011 | 837 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2003 | 313 | 0.040 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 1981 | 17 | 0.040 |
Why?
|
| Patient Compliance | 2 | 2011 | 481 | 0.040 |
Why?
|
| Ascites | 2 | 1973 | 111 | 0.040 |
Why?
|
| Extracellular Space | 7 | 1977 | 89 | 0.040 |
Why?
|
| Seasons | 1 | 2002 | 334 | 0.040 |
Why?
|
| Health Services Research | 1 | 2002 | 190 | 0.040 |
Why?
|
| Mitochondria | 2 | 1976 | 757 | 0.040 |
Why?
|
| Insect Bites and Stings | 1 | 1981 | 39 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 5 | 1990 | 434 | 0.040 |
Why?
|
| Bees | 1 | 1981 | 53 | 0.040 |
Why?
|
| Comorbidity | 3 | 2011 | 1625 | 0.040 |
Why?
|
| Immunoglobulin M | 6 | 1977 | 225 | 0.040 |
Why?
|
| Organizations, Nonprofit | 1 | 2000 | 24 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2003 | 419 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2011 | 4808 | 0.040 |
Why?
|
| Research | 2 | 1998 | 272 | 0.040 |
Why?
|
| Erythropoietin | 1 | 2001 | 111 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2001 | 233 | 0.040 |
Why?
|
| Phagocytosis | 1 | 1981 | 194 | 0.040 |
Why?
|
| Physician's Role | 1 | 2001 | 171 | 0.040 |
Why?
|
| Myocardium | 2 | 2003 | 1046 | 0.040 |
Why?
|
| Serotonin | 1 | 1981 | 226 | 0.040 |
Why?
|
| Serum Albumin | 2 | 1999 | 117 | 0.040 |
Why?
|
| Rifampin | 1 | 1980 | 136 | 0.040 |
Why?
|
| Egypt, Ancient | 1 | 1999 | 1 | 0.040 |
Why?
|
| Water Loss, Insensible | 1 | 1999 | 3 | 0.040 |
Why?
|
| Neutrophils | 2 | 1981 | 402 | 0.040 |
Why?
|
| Equipment and Supplies | 1 | 1999 | 28 | 0.040 |
Why?
|
| Greece, Ancient | 2 | 1989 | 9 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2003 | 414 | 0.040 |
Why?
|
| Prednisone | 5 | 1981 | 289 | 0.040 |
Why?
|
| Child | 9 | 2005 | 25890 | 0.040 |
Why?
|
| Nephrectomy | 1 | 1980 | 182 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 1998 | 65 | 0.040 |
Why?
|
| Tetracyclines | 1 | 1978 | 22 | 0.040 |
Why?
|
| Minocycline | 1 | 1978 | 42 | 0.040 |
Why?
|
| Safety | 1 | 1999 | 217 | 0.040 |
Why?
|
| Community Health Centers | 1 | 1978 | 41 | 0.040 |
Why?
|
| Morbidity | 1 | 1999 | 256 | 0.040 |
Why?
|
| Hyperglycemia | 2 | 1999 | 242 | 0.040 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1978 | 77 | 0.040 |
Why?
|
| Bacterial Infections | 2 | 1978 | 329 | 0.040 |
Why?
|
| Calibration | 2 | 2011 | 100 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2000 | 505 | 0.030 |
Why?
|
| Doxycycline | 1 | 1978 | 121 | 0.030 |
Why?
|
| Greek World | 1 | 1997 | 1 | 0.030 |
Why?
|
| Quality Control | 1 | 1997 | 126 | 0.030 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1998 | 95 | 0.030 |
Why?
|
| Water | 10 | 1976 | 200 | 0.030 |
Why?
|
| Furosemide | 5 | 1973 | 37 | 0.030 |
Why?
|
| Rats, Inbred Strains | 3 | 1987 | 236 | 0.030 |
Why?
|
| Community Health Services | 1 | 1978 | 93 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2000 | 399 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 1492 | 0.030 |
Why?
|
| Aspirin | 2 | 1996 | 231 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 1987 | 143 | 0.030 |
Why?
|
| Toxins, Biological | 1 | 1997 | 71 | 0.030 |
Why?
|
| Mitochondria, Liver | 1 | 1976 | 36 | 0.030 |
Why?
|
| Switzerland | 1 | 1996 | 15 | 0.030 |
Why?
|
| Cholesterol | 1 | 1999 | 575 | 0.030 |
Why?
|
| Occupational Exposure | 1 | 1997 | 138 | 0.030 |
Why?
|
| Hepatitis A | 2 | 1973 | 32 | 0.030 |
Why?
|
| Pediatrics | 1 | 2005 | 1215 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 1999 | 401 | 0.030 |
Why?
|
| Virus Diseases | 1 | 1978 | 290 | 0.030 |
Why?
|
| Photometry | 3 | 1974 | 4 | 0.030 |
Why?
|
| Lithium | 1 | 1975 | 71 | 0.030 |
Why?
|
| Hypertension, Malignant | 1 | 1975 | 6 | 0.030 |
Why?
|
| Liver Diseases | 2 | 1982 | 392 | 0.030 |
Why?
|
| Mercuric Chloride | 3 | 1983 | 3 | 0.030 |
Why?
|
| Natriuresis | 8 | 1977 | 37 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 1997 | 246 | 0.030 |
Why?
|
| Cyclic AMP | 3 | 1974 | 263 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 1975 | 131 | 0.030 |
Why?
|
| Adolescent | 14 | 2003 | 20624 | 0.030 |
Why?
|
| Acetaminophen | 1 | 1996 | 101 | 0.030 |
Why?
|
| Blood Volume | 2 | 1984 | 83 | 0.030 |
Why?
|
| Arabia | 1 | 1994 | 1 | 0.030 |
Why?
|
| Ascitic Fluid | 2 | 1973 | 31 | 0.030 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1976 | 228 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 1995 | 104 | 0.030 |
Why?
|
| Hospitalization | 1 | 2002 | 1906 | 0.030 |
Why?
|
| Drug Therapy, Combination | 3 | 2011 | 1200 | 0.030 |
Why?
|
| Pressure | 2 | 1971 | 136 | 0.030 |
Why?
|
| Blood Pressure | 5 | 2002 | 1421 | 0.030 |
Why?
|
| Endothelium | 3 | 1987 | 71 | 0.030 |
Why?
|
| Mice | 1 | 2011 | 19055 | 0.030 |
Why?
|
| Kidney Tubules, Distal | 4 | 1985 | 17 | 0.030 |
Why?
|
| Immersion | 2 | 1984 | 7 | 0.030 |
Why?
|
| Hepatitis, Viral, Human | 3 | 1978 | 45 | 0.030 |
Why?
|
| Regional Medical Programs | 1 | 1972 | 17 | 0.030 |
Why?
|
| Weights and Measures | 1 | 1972 | 6 | 0.030 |
Why?
|
| Hydronephrosis | 2 | 1970 | 38 | 0.020 |
Why?
|
| Ureter | 2 | 1971 | 100 | 0.020 |
Why?
|
| Blood Flow Velocity | 2 | 1971 | 468 | 0.020 |
Why?
|
| Complement System Proteins | 3 | 1979 | 61 | 0.020 |
Why?
|
| Chlorothiazide | 5 | 1976 | 12 | 0.020 |
Why?
|
| Anuria | 1 | 1971 | 13 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 1991 | 117 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2011 | 114 | 0.020 |
Why?
|
| Dye Dilution Technique | 1 | 1970 | 1 | 0.020 |
Why?
|
| North America | 1 | 2011 | 263 | 0.020 |
Why?
|
| Hypokalemia | 1 | 1970 | 41 | 0.020 |
Why?
|
| Propensity Score | 1 | 2011 | 261 | 0.020 |
Why?
|
| Immunoglobulin A | 3 | 1977 | 219 | 0.020 |
Why?
|
| Water-Electrolyte Imbalance | 2 | 1984 | 79 | 0.020 |
Why?
|
| Hematocrit | 4 | 1976 | 116 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 756 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 1991 | 214 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1991 | 226 | 0.020 |
Why?
|
| Optics and Photonics | 1 | 1970 | 123 | 0.020 |
Why?
|
| Urinary Tract Infections | 2 | 1989 | 307 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2011 | 273 | 0.020 |
Why?
|
| Blood Platelet Disorders | 1 | 1969 | 14 | 0.020 |
Why?
|
| Rome | 1 | 1989 | 10 | 0.020 |
Why?
|
| Hemorrhagic Disorders | 1 | 1969 | 22 | 0.020 |
Why?
|
| Diet | 2 | 1975 | 1195 | 0.020 |
Why?
|
| Age Factors | 3 | 1983 | 2998 | 0.020 |
Why?
|
| Gentamicins | 2 | 1983 | 96 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 2 | 2000 | 174 | 0.020 |
Why?
|
| Calcium Metabolism Disorders | 1 | 2008 | 3 | 0.020 |
Why?
|
| Mannitol | 6 | 1975 | 49 | 0.020 |
Why?
|
| Absorption | 3 | 1986 | 53 | 0.020 |
Why?
|
| Fluid Therapy | 1 | 1989 | 149 | 0.020 |
Why?
|
| Body Weight | 3 | 2002 | 1041 | 0.020 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 1989 | 83 | 0.020 |
Why?
|
| Leptospirosis | 2 | 1978 | 6 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 1976 | 1102 | 0.020 |
Why?
|
| Hypercalcemia | 4 | 1974 | 42 | 0.020 |
Why?
|
| Desoxycorticosterone | 1 | 1967 | 15 | 0.020 |
Why?
|
| Staphylococcal Infections | 2 | 1985 | 573 | 0.020 |
Why?
|
| Exchange Transfusion, Whole Blood | 2 | 1977 | 13 | 0.020 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 2 | 1977 | 8 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1740 | 0.020 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 1987 | 10 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2007 | 300 | 0.020 |
Why?
|
| Protein-Energy Malnutrition | 1 | 2007 | 76 | 0.020 |
Why?
|
| Syphilis | 2 | 1978 | 98 | 0.020 |
Why?
|
| Tritium | 3 | 1976 | 170 | 0.020 |
Why?
|
| Inulin | 3 | 1975 | 19 | 0.020 |
Why?
|
| Streptococcal Infections | 2 | 1980 | 248 | 0.020 |
Why?
|
| Malaria | 2 | 1978 | 105 | 0.020 |
Why?
|
| Thyroidectomy | 3 | 1980 | 112 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1971 | 447 | 0.020 |
Why?
|
| Specific Gravity | 1 | 1986 | 4 | 0.020 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 1980 | 228 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2008 | 5222 | 0.020 |
Why?
|
| Cyclophosphamide | 3 | 1977 | 426 | 0.020 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1986 | 36 | 0.020 |
Why?
|
| Basement Membrane | 3 | 1975 | 48 | 0.010 |
Why?
|
| Hematuria | 1 | 1986 | 55 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 1979 | 213 | 0.010 |
Why?
|
| Aminopyrine | 1 | 1964 | 7 | 0.010 |
Why?
|
| Oxygen Consumption | 2 | 1976 | 317 | 0.010 |
Why?
|
| Toxicology | 1 | 1964 | 8 | 0.010 |
Why?
|
| Infarction | 1 | 1985 | 24 | 0.010 |
Why?
|
| Capillaries | 2 | 1983 | 71 | 0.010 |
Why?
|
| Hyperkalemia | 1 | 1986 | 71 | 0.010 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1985 | 67 | 0.010 |
Why?
|
| Complement Activation | 1 | 1984 | 53 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 2172 | 0.010 |
Why?
|
| Cellulose | 1 | 1984 | 30 | 0.010 |
Why?
|
| Microcirculation | 1 | 1985 | 117 | 0.010 |
Why?
|
| Drug Therapy | 1 | 1964 | 94 | 0.010 |
Why?
|
| Leukocytes | 2 | 1977 | 223 | 0.010 |
Why?
|
| Hepatitis B Antigens | 2 | 1975 | 10 | 0.010 |
Why?
|
| Body Water | 2 | 1974 | 90 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2007 | 1338 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 2006 | 298 | 0.010 |
Why?
|
| Social Support | 1 | 1986 | 384 | 0.010 |
Why?
|
| Abscess | 1 | 1985 | 140 | 0.010 |
Why?
|
| Systole | 1 | 1983 | 206 | 0.010 |
Why?
|
| Insulin | 2 | 1982 | 1260 | 0.010 |
Why?
|
| Necrosis | 1 | 1983 | 221 | 0.010 |
Why?
|
| Carbon Dioxide | 3 | 1986 | 289 | 0.010 |
Why?
|
| Blood Proteins | 3 | 1974 | 136 | 0.010 |
Why?
|
| Acidosis, Renal Tubular | 2 | 1973 | 6 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 1986 | 469 | 0.010 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 1982 | 9 | 0.010 |
Why?
|
| Hypersensitivity | 1 | 1984 | 194 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 1982 | 64 | 0.010 |
Why?
|
| Digoxin | 3 | 1971 | 44 | 0.010 |
Why?
|
| Body Temperature | 1 | 2002 | 130 | 0.010 |
Why?
|
| Graft Rejection | 2 | 1977 | 630 | 0.010 |
Why?
|
| Recurrence | 1 | 1986 | 1472 | 0.010 |
Why?
|
| Urologic Diseases | 1 | 1982 | 45 | 0.010 |
Why?
|
| Kidney Cortex | 3 | 1977 | 20 | 0.010 |
Why?
|
| Sulfonamides | 2 | 1975 | 287 | 0.010 |
Why?
|
| Blood Glucose | 2 | 1986 | 1196 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 2004 | 319 | 0.010 |
Why?
|
| Adenosine Triphosphate | 2 | 1981 | 298 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 2004 | 1157 | 0.010 |
Why?
|
| Heart | 2 | 1976 | 749 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 1981 | 61 | 0.010 |
Why?
|
| Iodine Isotopes | 2 | 1971 | 5 | 0.010 |
Why?
|
| Kidney Medulla | 3 | 1975 | 19 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2008 | 17540 | 0.010 |
Why?
|
| Indocyanine Green | 2 | 1971 | 62 | 0.010 |
Why?
|
| Haplorhini | 2 | 1977 | 121 | 0.010 |
Why?
|
| Regional Blood Flow | 4 | 1977 | 228 | 0.010 |
Why?
|
| Inflammation | 1 | 2007 | 1595 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 3857 | 0.010 |
Why?
|
| Arthritis, Infectious | 1 | 1980 | 67 | 0.010 |
Why?
|
| Hypertonic Solutions | 3 | 1974 | 20 | 0.010 |
Why?
|
| Infusions, Parenteral | 4 | 1974 | 100 | 0.010 |
Why?
|
| Spectrophotometry | 4 | 1972 | 62 | 0.010 |
Why?
|
| Tuberculosis, Renal | 1 | 1978 | 3 | 0.010 |
Why?
|
| Infectious Mononucleosis | 1 | 1978 | 15 | 0.010 |
Why?
|
| Coxsackievirus Infections | 1 | 1978 | 10 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1979 | 65 | 0.010 |
Why?
|
| Mumps | 1 | 1978 | 12 | 0.010 |
Why?
|
| Chickenpox | 1 | 1978 | 22 | 0.010 |
Why?
|
| Leprosy | 1 | 1978 | 19 | 0.010 |
Why?
|
| Hospitals, District | 1 | 1978 | 6 | 0.010 |
Why?
|
| Half-Life | 1 | 1978 | 162 | 0.010 |
Why?
|
| Candidiasis | 2 | 1976 | 138 | 0.010 |
Why?
|
| Syphilis, Congenital | 1 | 1978 | 30 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1979 | 175 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 9944 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2002 | 1506 | 0.010 |
Why?
|
| Texas | 3 | 1978 | 3716 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1978 | 261 | 0.010 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 1978 | 95 | 0.010 |
Why?
|
| European Union | 1 | 1997 | 13 | 0.010 |
Why?
|
| Infant | 3 | 2003 | 13240 | 0.010 |
Why?
|
| Medical Audit | 1 | 1978 | 104 | 0.010 |
Why?
|
| In Vitro Techniques | 2 | 1976 | 993 | 0.010 |
Why?
|
| Parotid Gland | 1 | 1977 | 21 | 0.010 |
Why?
|
| Mitochondrial Swelling | 1 | 1976 | 7 | 0.010 |
Why?
|
| Polyarteritis Nodosa | 1 | 1976 | 8 | 0.010 |
Why?
|
| Injections, Intravenous | 3 | 1975 | 252 | 0.010 |
Why?
|
| Phlorhizin | 1 | 1976 | 1 | 0.010 |
Why?
|
| Methylglucosides | 1 | 1976 | 2 | 0.010 |
Why?
|
| Diphenylamine | 1 | 1976 | 5 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1976 | 27 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1977 | 281 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 1976 | 75 | 0.010 |
Why?
|
| Sulfhydryl Compounds | 1 | 1976 | 61 | 0.010 |
Why?
|
| Disease Outbreaks | 1 | 1998 | 330 | 0.010 |
Why?
|
| Deoxyglucose | 1 | 1976 | 42 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 1977 | 103 | 0.010 |
Why?
|
| Complement C3 | 1 | 1976 | 54 | 0.010 |
Why?
|
| Hydrochlorothiazide | 1 | 1976 | 60 | 0.010 |
Why?
|
| Kinetics | 1 | 1978 | 1357 | 0.010 |
Why?
|
| Procainamide | 1 | 1976 | 5 | 0.010 |
Why?
|
| Pneumococcal Infections | 1 | 1978 | 276 | 0.010 |
Why?
|
| Quinidine | 1 | 1976 | 12 | 0.010 |
Why?
|
| Blood Vessels | 1 | 1976 | 109 | 0.010 |
Why?
|
| Nephrons | 1 | 1976 | 21 | 0.010 |
Why?
|
| Benzothiadiazines | 1 | 1975 | 5 | 0.010 |
Why?
|
| Lidocaine | 1 | 1976 | 48 | 0.010 |
Why?
|
| Immunoelectrophoresis | 1 | 1975 | 10 | 0.010 |
Why?
|
| Latex Fixation Tests | 1 | 1975 | 5 | 0.010 |
Why?
|
| Chlorides | 4 | 1982 | 108 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1975 | 158 | 0.010 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 1975 | 34 | 0.010 |
Why?
|
| Plasma | 1 | 1976 | 105 | 0.010 |
Why?
|
| Homozygote | 2 | 1974 | 570 | 0.010 |
Why?
|
| Acetylcholine | 2 | 1972 | 87 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1975 | 69 | 0.010 |
Why?
|
| Tissue Extracts | 1 | 1974 | 15 | 0.010 |
Why?
|
| Oliguria | 1 | 1974 | 20 | 0.010 |
Why?
|
| Immunoassay | 1 | 1975 | 139 | 0.010 |
Why?
|
| Pericarditis | 1 | 1975 | 43 | 0.010 |
Why?
|
| Amphotericin B | 1 | 1975 | 91 | 0.010 |
Why?
|
| Cysteine | 1 | 1975 | 143 | 0.010 |
Why?
|
| Sex Factors | 1 | 1979 | 1387 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 1976 | 318 | 0.010 |
Why?
|
| Child, Preschool | 3 | 2003 | 14884 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1976 | 489 | 0.010 |
Why?
|
| Klebsiella Infections | 1 | 1975 | 62 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1976 | 271 | 0.010 |
Why?
|
| Galactose | 1 | 1974 | 57 | 0.010 |
Why?
|
| Jaundice | 1 | 1974 | 27 | 0.010 |
Why?
|
| Manometry | 1 | 1974 | 73 | 0.010 |
Why?
|
| Beta-Globulins | 1 | 1973 | 2 | 0.010 |
Why?
|
| Dietary Carbohydrates | 1 | 1974 | 117 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 1975 | 255 | 0.010 |
Why?
|
| Nutritional Requirements | 1 | 1974 | 180 | 0.010 |
Why?
|
| Acetazolamide | 2 | 1971 | 31 | 0.010 |
Why?
|
| Coronary Disease | 1 | 1978 | 721 | 0.010 |
Why?
|
| Methoxyflurane | 1 | 1973 | 1 | 0.010 |
Why?
|
| Phenacetin | 1 | 1973 | 3 | 0.010 |
Why?
|
| Cystinuria | 1 | 1973 | 4 | 0.010 |
Why?
|
| Ethacrynic Acid | 2 | 1970 | 4 | 0.010 |
Why?
|
| Cyanides | 2 | 1970 | 9 | 0.010 |
Why?
|
| Progressive Patient Care | 1 | 1972 | 1 | 0.010 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1974 | 152 | 0.010 |
Why?
|
| Regional Health Planning | 1 | 1972 | 6 | 0.010 |
Why?
|
| Hypocalcemia | 1 | 1973 | 38 | 0.010 |
Why?
|
| Tissue Preservation | 1 | 1972 | 16 | 0.010 |
Why?
|
| Urinary Catheterization | 2 | 1970 | 82 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 1972 | 88 | 0.010 |
Why?
|
| Muscle Proteins | 1 | 1976 | 425 | 0.010 |
Why?
|
| Morphogenesis | 1 | 1974 | 215 | 0.010 |
Why?
|
| Epithelial Cells | 2 | 1974 | 937 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1974 | 323 | 0.010 |
Why?
|
| Mass Screening | 1 | 1998 | 840 | 0.010 |
Why?
|
| Prostaglandins | 1 | 1972 | 48 | 0.010 |
Why?
|
| Inclusion Bodies | 1 | 1972 | 48 | 0.010 |
Why?
|
| Health Facilities | 1 | 1972 | 66 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1974 | 1044 | 0.010 |
Why?
|
| Protein Binding | 1 | 1976 | 1859 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2003 | 3506 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1976 | 477 | 0.010 |
Why?
|
| Influenza, Human | 1 | 1978 | 699 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1972 | 204 | 0.010 |
Why?
|
| Amino Acids | 1 | 1974 | 688 | 0.010 |
Why?
|
| Syndrome | 1 | 1974 | 1167 | 0.010 |
Why?
|
| Bence Jones Protein | 1 | 1971 | 1 | 0.010 |
Why?
|
| Myeloma Proteins | 1 | 1971 | 4 | 0.010 |
Why?
|
| Blood Viscosity | 1 | 1971 | 13 | 0.010 |
Why?
|
| Adenine Nucleotides | 1 | 1971 | 42 | 0.010 |
Why?
|
| Chromium Isotopes | 1 | 1971 | 1 | 0.010 |
Why?
|
| Ouabain | 1 | 1971 | 29 | 0.010 |
Why?
|
| Dinitrophenols | 1 | 1970 | 5 | 0.010 |
Why?
|
| Chlormerodrin | 1 | 1970 | 1 | 0.010 |
Why?
|
| Methods | 1 | 1970 | 143 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1975 | 703 | 0.010 |
Why?
|
| Allopurinol | 1 | 1971 | 76 | 0.010 |
Why?
|
| Amyloidosis | 1 | 1971 | 73 | 0.010 |
Why?
|
| Fiber Optic Technology | 1 | 1970 | 46 | 0.010 |
Why?
|
| Carbon Isotopes | 1 | 1970 | 279 | 0.010 |
Why?
|
| Functional Laterality | 1 | 1971 | 196 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2003 | 8623 | 0.010 |
Why?
|
| Amides | 1 | 1970 | 87 | 0.010 |
Why?
|
| Nephrosclerosis | 1 | 1969 | 7 | 0.000 |
Why?
|
| Bilirubin | 1 | 1970 | 131 | 0.000 |
Why?
|
| Glycolysis | 1 | 1970 | 173 | 0.000 |
Why?
|
| Loop of Henle | 3 | 1974 | 4 | 0.000 |
Why?
|
| Blood Cell Count | 1 | 1969 | 70 | 0.000 |
Why?
|
| Blood Coagulation Tests | 1 | 1969 | 62 | 0.000 |
Why?
|
| Tissue Donors | 1 | 1972 | 523 | 0.000 |
Why?
|
| Blood Coagulation Factors | 1 | 1969 | 35 | 0.000 |
Why?
|
| Diet Therapy | 1 | 1969 | 43 | 0.000 |
Why?
|
| Lung | 1 | 1976 | 1577 | 0.000 |
Why?
|
| Clinical Protocols | 1 | 1989 | 245 | 0.000 |
Why?
|
| Cysts | 1 | 1969 | 104 | 0.000 |
Why?
|
| Blood Coagulation | 1 | 1969 | 134 | 0.000 |
Why?
|
| Infusions, Intravenous | 1 | 1989 | 572 | 0.000 |
Why?
|
| Liver | 1 | 1975 | 1879 | 0.000 |
Why?
|
| Proteins | 1 | 1973 | 1101 | 0.000 |
Why?
|
| Microinjections | 1 | 1985 | 51 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1977 | 2578 | 0.000 |
Why?
|
| Brain | 1 | 1976 | 3224 | 0.000 |
Why?
|
| Isotonic Solutions | 2 | 1975 | 36 | 0.000 |
Why?
|
| Wakefulness | 1 | 1984 | 104 | 0.000 |
Why?
|
| Cytoplasm | 1 | 1983 | 304 | 0.000 |
Why?
|
| Water Deprivation | 2 | 1972 | 4 | 0.000 |
Why?
|
| Receptors, Drug | 2 | 1971 | 40 | 0.000 |
Why?
|
| Biological Transport | 2 | 1972 | 371 | 0.000 |
Why?
|
| Hypotonic Solutions | 2 | 1970 | 14 | 0.000 |
Why?
|
| Binding Sites | 2 | 1973 | 1384 | 0.000 |
Why?
|
| Vascular Resistance | 1 | 1977 | 202 | 0.000 |
Why?
|
| Inclusion Bodies, Viral | 1 | 1975 | 11 | 0.000 |
Why?
|
| Papio | 1 | 1975 | 60 | 0.000 |
Why?
|
| Allantoin | 1 | 1975 | 1 | 0.000 |
Why?
|
| Cryptococcosis | 1 | 1975 | 44 | 0.000 |
Why?
|
| Histoplasmosis | 1 | 1975 | 49 | 0.000 |
Why?
|
| Injections, Intraperitoneal | 1 | 1974 | 74 | 0.000 |
Why?
|
| Adenosine Monophosphate | 1 | 1974 | 42 | 0.000 |
Why?
|
| Corticosterone | 1 | 1974 | 63 | 0.000 |
Why?
|
| Halogens | 1 | 1973 | 3 | 0.000 |
Why?
|
| Barbiturates | 1 | 1973 | 7 | 0.000 |
Why?
|
| Drainage | 1 | 1975 | 265 | 0.000 |
Why?
|
| Salicylates | 1 | 1973 | 55 | 0.000 |
Why?
|
| Biopsy, Needle | 1 | 1974 | 237 | 0.000 |
Why?
|
| Fibrinogen | 1 | 1974 | 163 | 0.000 |
Why?
|
| Cells | 1 | 1973 | 25 | 0.000 |
Why?
|
| Epithelium | 1 | 1974 | 366 | 0.000 |
Why?
|
| Fasting | 1 | 1974 | 308 | 0.000 |
Why?
|
| Iothalamic Acid | 1 | 1972 | 3 | 0.000 |
Why?
|
| Capillary Permeability | 1 | 1972 | 77 | 0.000 |
Why?
|
| Ferricyanides | 1 | 1972 | 1 | 0.000 |
Why?
|
| Iodine Radioisotopes | 1 | 1972 | 79 | 0.000 |
Why?
|
| Cell Division | 1 | 1974 | 774 | 0.000 |
Why?
|
| Blood | 1 | 1972 | 109 | 0.000 |
Why?
|
| Procarbazine | 1 | 1971 | 12 | 0.000 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 1972 | 35 | 0.000 |
Why?
|
| Serum Globulins | 1 | 1971 | 8 | 0.000 |
Why?
|
| Plasmapheresis | 1 | 1971 | 35 | 0.000 |
Why?
|
| Stimulation, Chemical | 1 | 1971 | 66 | 0.000 |
Why?
|
| Coma | 1 | 1971 | 57 | 0.000 |
Why?
|
| Carbonic Anhydrases | 1 | 1971 | 26 | 0.000 |
Why?
|
| Ultracentrifugation | 1 | 1971 | 23 | 0.000 |
Why?
|
| Drug Combinations | 1 | 1972 | 285 | 0.000 |
Why?
|
| Pyruvate Kinase | 1 | 1971 | 11 | 0.000 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1971 | 67 | 0.000 |
Why?
|
| Depression, Chemical | 1 | 1970 | 43 | 0.000 |
Why?
|
| Thiosulfates | 1 | 1969 | 7 | 0.000 |
Why?
|
| Injections, Intra-Arterial | 1 | 1969 | 18 | 0.000 |
Why?
|
| Enzyme Activation | 1 | 1971 | 650 | 0.000 |
Why?
|
| Deafness | 1 | 1970 | 87 | 0.000 |
Why?
|
| Fibroblasts | 1 | 1974 | 928 | 0.000 |
Why?
|
| Intubation, Gastrointestinal | 1 | 1969 | 54 | 0.000 |
Why?
|
| Lactates | 1 | 1969 | 102 | 0.000 |
Why?
|
| Cataract | 1 | 1970 | 174 | 0.000 |
Why?
|
| Bile Acids and Salts | 1 | 1971 | 259 | 0.000 |
Why?
|
| Bendroflumethiazide | 1 | 1966 | 1 | 0.000 |
Why?
|
| Chlorthalidone | 1 | 1966 | 27 | 0.000 |
Why?
|
| Aminohippuric Acids | 1 | 1966 | 2 | 0.000 |
Why?
|
| Pedigree | 1 | 1970 | 1728 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1975 | 3178 | 0.000 |
Why?
|